Table 3.
Multivariate logistic regression models for Gleason score (3+3) upgrade
| Characteristics | OR | 95% CI | P |
|---|---|---|---|
| Age ³60 years (yes vs no) | 2.06 | 1.13–3.78 | 0.019* |
| Ethnicity | |||
| Caucasian | Reference | ||
| African American | 1.63 | 0.60–4.47 | 0.341 |
| Hispanic | 0.41 | 0.16–1.01 | 0.052 |
| PSA ³4.3 ng ml−1 (yes vs no) | 1.67 | 0.89–3.15 | 0.111 |
| PSAD ³0.13 ng ml−1 (yes vs no) | 2.53 | 1.33–4.82 | 0.005* |
| Clinical stage (cT2 vs cT1) | 3.31 | 1.14–9.58 | 0.027* |
| Total number of biopsy cores ³12 (yes vs no) | 0.57 | 0.31–1.04 | 0.068 |
| Core+ ³2 (yes vs no) | 1.44 | 0.77–2.68 | 0.252 |
| ASAP/HGPIN status (HGPIN and/or ASAP vs None) |
1.90 | 1.06–3.40 | 0.031* |
| Maximum core+ length ³2 mm (yes vs no) | 1.54 | 0.71–3.33 | 0.272 |
| Percentage of tumor in maximum positive core ³13% (yes vs no) | 1.73 | 0.79–3.80 | 0.172 |
| Percentage of PCa in total specimen ³4% (yes vs no) | 1.10 | 0.60–1.99 | 0.764 |
*P<0.05 was considered statistically significant. ASAP: atypical small acinar proliferation; CI: confidence interval; HGPIN: high-grade prostatic intraepithelial neoplasia; OR: odds ratio; PCa: prostate cancer; PSA: prostate-specific antigen; PSAD: prostate-specific antigen density